Pliant Therapeutics, Inc.
PLRXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Pliant Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Pliant Therapeutics, Inc. — 10-K filed Mar 3, 2025
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 7 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 12, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Pliant Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-01-20 · Coulie Bernard: Larger than all 68 other insider sales of Common Stock on file. SEC filing
- 2025-01-17 · Coulie Bernard: Larger than 65 of the 68 other insider sales of Common Stock on file. SEC filing
- 2024-07-10 · Coulie Bernard: Larger than 64 of the 68 other insider sales of Common Stock on file. SEC filing
- 2023-07-17 · Coulie Bernard: Larger than 67 of the 68 other insider sales of Common Stock on file. SEC filing
- 2023-03-30 · Coulie Bernard: Larger than 63 of the 68 other insider sales of Common Stock on file. SEC filing
- 2023-01-23 · Cummings Keith Lamont: Larger than 62 of the 68 other insider sales of Common Stock on file. SEC filing
- 2023-01-23 · Lefebvre Eric: Larger than 66 of the 68 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-01-20 | Kuo Minnie · Chief Operating Officer | Common Stock | S — Open market or private sale | −6,917 | 1.28 | SEC filing |
| 2026-01-20 | Cheung Lily · Chief Human Resource Officer | Common Stock | S — Open market or private sale | −7,534 | 1.28 | SEC filing |
| 2026-01-20 | Cummings Keith Lamont · Chief Financial Officer | Common Stock | S — Open market or private sale | −24,002 | 1.28 | SEC filing |
| 2026-01-20 | Coulie Bernard · President and CEO | Common Stock | S — Open market or private sale | −89,375 | 1.28 | SEC filing |
| 2025-01-22 | Ouimette Mike · General Counsel & Corp. Sec'y | Common Stock | S — Open market or private sale | −10,230 | 10.99 | SEC filing |
| 2025-01-17 | Hull Hans · Chief Business Officer | Common Stock | S — Open market or private sale | −15,936 | 11.20 | SEC filing |
| 2025-01-17 | Cheung Lily · Chief Human Resource Officer | Common Stock | S — Open market or private sale | −3,740 | 11.20 | SEC filing |
| 2025-01-17 | Cummings Keith Lamont · Chief Financial Officer | Common Stock | S — Open market or private sale | −20,148 | 11.20 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-11 | Huh Hoyoung · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +70,000 | SEC filing |
| 2026-06-11 | Krognes Steve E. · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +70,000 | SEC filing |
| 2026-06-11 | MCCOURT Thomas A · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +70,000 | SEC filing |
| 2026-06-11 | CROWELL GAYLE A · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +70,000 | SEC filing |
| 2026-06-11 | Curnutte John T · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +70,000 | SEC filing |
| 2026-06-11 | Cline Darren S · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +70,000 | SEC filing |
| 2026-04-17 | Coulie Bernard · President and CEO | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +206,300 | SEC filing |
| 2026-04-17 | Kuo Minnie · Chief Operating Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +55,200 | SEC filing |
Showing 8 of 20 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-04-17 | Coulie Bernard · President and CEO | Stock Option (Right to Buy) | D — Disposition to the issuer | −325,000 | SEC filing |
| 2026-04-17 | Kuo Minnie · Chief Operating Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −55,200 | SEC filing |
| 2026-04-17 | Cummings Keith Lamont · Chief Financial Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −124,000 | SEC filing |
| 2026-04-17 | Coulie Bernard · President and CEO | Stock Option (Right to Buy) | D — Disposition to the issuer | −327,262 | SEC filing |
| 2026-04-17 | Cheung Lily · Chief Human Resource Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −123,000 | SEC filing |
| 2026-04-17 | Coulie Bernard · President and CEO | Stock Option (Right to Buy) | D — Disposition to the issuer | −146,841 | SEC filing |
| 2026-04-17 | Coulie Bernard · President and CEO | Stock Option (Right to Buy) | D — Disposition to the issuer | −250,000 | SEC filing |
| 2026-04-17 | Cummings Keith Lamont · Chief Financial Officer | Stock Option (Right to Buy) | D — Disposition to the issuer | −76,047 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.